Fresenius Medical Care, the world's largest provider of dialysis products and services, expects continued strong growth in the coming years. At today's Annual General Meeting in Frankfurt, Rice Powell, chief executive officer, confirmed the long-term targets announced in April. The company expects sales to almost double to about $28 billion in 2020 from $14.6 billion last year. This represents a cumulative average growth rate (CAGR) of about 10 percent annually between 2015 and 2020, with high-single-digit increases in net income and earnings per share over the same period.

"These are ambitious targets - no question," Rice Powell said in his speech to shareholders. "But with our unwavering focus on growth and efficiency, I am certain that we will meet the company's long-term goals. We are the global leaders in dialysis, and our company is continuing to shape the future of the dialysis industry. By expanding into dialysis-related medical services we will be able to better coordinate care, to the benefit of all our patients."

Rice Powell also confirmed the company's guidance for 2014. Fresenius Medical Care expects revenue to be at around $15.2 billion, translating into a growth rate of around 4%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014.
With a large majority of 99.85%, shareholders approved Fresenius Medical Care's 17th consecutive dividend increase. The dividend will be raised to €0.77 from €0.75 per ordinary share.

A shareholder majority of over 99% approved the actions of both the Management and Supervisory Boards in 2013.

At the annual general meeting, 74.28% of the subscribed capital was represented.


distributed by